Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lecithinized superoxide dismutase

Drug Profile

Lecithinized superoxide dismutase

Alternative Names: Superoxide dismutase-lecithinized

Latest Information Update: 14 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seikagaku Corporation
  • Developer Asahi Glass; Seikagaku Corporation
  • Class Anti-ischaemics
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute lung injury; HIV infections; Myocardial ischaemia

Most Recent Events

  • 06 May 2003 Preclinical trials in HIV infections treatment in Japan (unspecified route)
  • 06 May 2003 Preclinical trials in Myocardial ischaemia in Japan (unspecified route)
  • 22 Nov 2002 No development reported - Phase-II for Acute lung injury in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top